Phibro Animal Health Corp ( (PAHC) ) has released its Q4 earnings. Here is a breakdown of the information Phibro Animal Health Corp presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Phibro Animal Health Corporation is a global leader in animal health and mineral nutrition, providing solutions to enhance the health of farm and companion animals. The company operates primarily in the animal health sector, offering a diverse portfolio that includes medicated feed additives, nutritional specialties, and vaccines.
Phibro Animal Health Corporation reported strong financial results for the fourth quarter and fiscal year ending June 30, 2025, with significant growth in net sales and net income. The company achieved a 27% increase in annual net sales and a 65% rise in adjusted EBITDA, driven by robust demand across its product lines, including medicated feed additives, nutritional specialties, and vaccines.
Key financial highlights include a 39% increase in net sales for the fourth quarter, reaching $378.7 million, and a 39% rise in adjusted net income to $23.2 million. For the full fiscal year, net sales grew by 27% to $1,296.2 million, while adjusted net income surged by 76% to $84.9 million. The company’s strategic initiatives, such as the Phibro Forward program, have contributed to unlocking efficiencies and driving sustainable growth.
Looking ahead, Phibro Animal Health Corporation has provided financial guidance for fiscal year 2026, projecting net sales between $1.43 billion and $1.48 billion, and adjusted EBITDA in the range of $225 million to $235 million. The company remains confident in its growth trajectory, supported by its strong portfolio and disciplined execution, aiming to deliver long-term value for customers and shareholders.